1700014B07Rik Activators
1700014B07Rik Activators encompass a diverse array of chemical compounds that indirectly heighten the activity of 1700014B07Rik through discrete signaling mechanisms. Forskolin, by enhancing cAMP levels, indirectly augments the functional activity of 1700014B07Rik via PKA activation, which is known to phosphorylate various proteins that could be part of 1700014B07Rik's signaling network. Similarly, compounds like EGCG and Genistein diminish competitive signaling by inhibiting certain kinases, which may permit the preferential activation of pathways that include 1700014B07Rik. Ionomycin and A23187 elevate intracellular calcium, thereby activating calcium-dependent proteins and pathways that might include 1700014B07Rik, enhancing its activity.
1700014B07Rik Activators are a suite of chemical entities that indirectly bolster the activity of 1700014B07Rik through various specific signaling conduits. Forskolin, through its elevation of intracellular cAMP levels, indirectly promotes the functional activity of 1700014B07Rik by activating protein kinase A, which might phosphorylate substrates within the same signaling pathways as 1700014B07Rik, thus augmenting its activity. Epigallocatechin gallate, a kinase inhibitor, and Genistein, a tyrosine kinase inhibitor, potentially allow for pathways involving 1700014B07Rik to become more active by decreasing competing kinase signal transduction, which could enhance the function of 1700014B07Rik by reducing noise in the signaling channels. The action of PMA as a PKC activator could similarly enhance the activity of 1700014B07Rik by affecting substrates and pathways that intersect with those the protein is involved in.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG is a kinase inhibitor that may reduce competitive signal transduction activities, potentially allowing for the signaling pathways that involve 1700014B07Rik to be more active and thus enhancing its function. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium concentrations, which might activate calcium-dependent proteins and signal transduction pathways that could lead to the activation of 1700014B07Rik. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which may phosphorylate substrates and affect pathways that 1700014B07Rik is involved in, thereby enhancing the protein's activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that can alter downstream signaling, potentially reducing negative regulation and enhancing pathways where 1700014B07Rik is active. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
S1P is involved in the sphingolipid signaling pathway, which may intersect with pathways involving 1700014B07Rik, leading to its activation through complex lipid signaling cascades. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin disrupts calcium homeostasis by inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), which can lead to the activation of calcium-dependent pathways potentially involving 1700014B07Rik. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor that interferes with the MAPK/ERK pathway, which may shift the signaling equilibrium to favor activation of pathways where 1700014B07Rik is involved. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which could selectively enhance signaling pathways that involve 1700014B07Rik by diminishing competing stress response signals. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 is another calcium ionophore that increases intracellular calcium, activating calcium-dependent signaling pathways that may lead to the indirect activation of 1700014B07Rik. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that may potentiate signaling pathways associated with 1700014B07Rik by reducing competitive phosphorylation events. | ||||||